Norberto Perico

Norberto Perico's AcademicInfluence.com Rankings

Norberto Perico

Medical

#2395

World Rank

#2817

Historical Rank

Epidemiology

#430

World Rank

#450

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Norberto Perico Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Norberto Perico's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) (11746)
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) (8152)
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012) (7185)
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (5789)
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) (5270)
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2015) (4436)
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (4388)
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (4293)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2020) (4169)
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013 (2015) (4152)
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (3330)
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (3308)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 (2020) (2362)
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (1869)
Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2020) (1788)
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition (2015) (1618)
Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (1580)
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (1515)
Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2019) (1485)
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (1477)
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) (1475)
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2015) (1241)
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010 (2012) (1159)
Delayed graft function in kidney transplantation (2004) (929)
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. (2004) (748)
Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (623)
Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016) (579)
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015 (2016) (549)
Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018) (538)
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 (2020) (522)
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017) (495)
Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study. (2016) (475)
Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015 (2017) (452)
Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells1 (2008) (429)
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. (2005) (417)
Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015 (2016) (394)
Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice (2008) (369)
Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. (1995) (341)
Mechanisms of Disease: pre-eclampsia (2005) (329)
Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. (2016) (308)
Five insights from the Global Burden of Disease Study 2019 (2020) (291)
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. (2011) (278)
Chronic Renal Diseases: Renoprotective Benefits of ReninAngiotensin System Inhibition (2002) (276)
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. (2007) (246)
Tumor necrosis factor induces glomerular damage in the rabbit. (1989) (245)
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. (2002) (229)
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial (2013) (225)
Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. (1993) (223)
Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. (1993) (220)
Child and Adolescent Health From 1990 to 2015 (2017) (217)
Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation (2004) (203)
Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. (1986) (195)
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. (2002) (192)
Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. (1993) (186)
Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. (1990) (186)
Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. (1992) (169)
Increased renal endothelin production in rats with reduced renal mass. (1991) (168)
Recellularization of well-preserved acellular kidney scaffold using embryonic stem cells. (2014) (168)
Global Cardiovascular and Renal Outcomes of Reduced GFR. (2017) (167)
Hepatitis C infection and chronic renal diseases. (2009) (166)
Maintenance Dialysis throughout the World in Years 1990 and 2010. (2015) (163)
New therapeutics that antagonize endothelin: promises and frustrations (2002) (158)
Cyclosporine-induced renal dysfunction in experimental animals and humans. (1991) (157)
Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation (2012) (157)
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial (2004) (155)
Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation (2013) (154)
Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. (1998) (153)
Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study (2018) (150)
Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts. (1993) (141)
Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. (1994) (137)
Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. (1991) (133)
Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation (2005) (129)
Bone marrow-derived mesenchymal stem cells improve islet graft function in diabetic rats. (2009) (129)
Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. (1998) (128)
Timed urine collections are not needed to measure urine protein excretion in clinical practice. (2006) (125)
Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies (2013) (124)
Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation (1991) (121)
Mesenchymal stromal cells in renal transplantation: opportunities and challenges (2016) (120)
Sirolimus therapy to halt the progression of ADPKD. (2010) (116)
Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. (1991) (116)
Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. (1990) (115)
Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. (1996) (113)
Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. (1999) (113)
Role of Insulin and Atrial Natriuretic Peptide in Sodium Retention in Insulin-Treated IDDM Patients During Isotonic Volume Expansion (1990) (113)
The aggravating mechanisms of aldosterone on kidney fibrosis. (2008) (111)
A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group (2017) (110)
Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019 (2021) (108)
Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury (2007) (108)
The Impact of Kidney Development on the Life Course: A Consensus Document for Action (2017) (108)
A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes (2018) (105)
ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. (1999) (101)
Chronic kidney disease: a research and public health priority. (2012) (98)
Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. (1999) (98)
C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. (2007) (94)
Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients (2001) (93)
Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection (2008) (93)
THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE (1992) (92)
Application of newer clearance techniques for the determination of glomerular filtration rate. (1998) (92)
Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study (2010) (90)
The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. (1998) (85)
Influence of Co‐Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation (2005) (83)
Nephrotoxic aspects of cyclosporine. (2004) (79)
Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). (2010) (78)
Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. (1986) (77)
Long-term follow-up of recovered patients with COVID-19 (2021) (76)
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons Learned from First Clinical Trials (2013) (75)
Renal injury induced by long-term administration of cyclosporin A to rats. (1987) (73)
Mesenchymal stromal cells to promote solid organ transplantation tolerance (2013) (72)
Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. (1994) (72)
Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? (1986) (72)
Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. (2002) (71)
The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis (2020) (70)
Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. (1988) (70)
Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group (2009) (70)
ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. (1999) (70)
From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy (2004) (70)
Burden of CKD, proteinuria, and cardiovascular risk among Chinese, Mongolian, and Nepalese participants in the International Society of Nephrology screening programs. (2010) (69)
ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. (2009) (69)
Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia. (2005) (69)
Prevention programmes of progressive renal disease in developing nations (Review Article) (2006) (69)
Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase products. (1991) (67)
Long‐Term Renal Allograft Function on a Tacrolimus‐Based, Pred‐Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF † (2006) (67)
Glomerular filtration rate determined from a single plasma sample after intravenous iohexol injection: is it reliable? (1996) (65)
In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development (2013) (65)
Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. (1989) (65)
Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. (2001) (63)
Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. (1997) (63)
Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. (1996) (62)
Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study (2012) (62)
Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing (2004) (61)
Paricalcitol for secondary hyperparathyroidism in renal transplantation. (2015) (61)
Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. (2013) (60)
Community-based screening for chronic kidney disease, hypertension and diabetes in Dharan. (2013) (59)
Measurement of glomerular filtration rate. (1997) (58)
Kidney failure: aims for the next 10 years and barriers to success (2013) (57)
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. (2009) (57)
von Willebrand factor cleaving protease ( ADAMTS 13 ) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (2002) (56)
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019 (2022) (54)
Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. (1997) (54)
PHARMACOKINETICS OF MYCOPHENOLATE SODIUM AND COMPARISON WITH THE MOFETIL FORMULATION IN KIDNEY TRANSPLANT RECIPIENTS. (2006) (54)
Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats (1992) (54)
Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17 (2020) (52)
Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017 (2019) (51)
Tackling the Shortage of Donor Kidneys: How to Use the Best that We Have (2003) (51)
Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy (2018) (50)
INCREASED URINARY EXCRETION OF ENDOTHELIN‐1 AND ITS PRECURSOR, BIG‐ENDOTHELIN-1, IN RATS CHRONICALLY TREATED WITH CYCLOSPORINE (1991) (48)
Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017 (2020) (47)
Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017 (2020) (47)
Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. (2017) (45)
Prevention of transplant rejection: current treatment guidelines and future developments. (1997) (45)
Pharmacogenetics of Immunosuppressants: Progress, Pitfalls and Promises (2008) (44)
Mapping child growth failure across low- and middle-income countries (2020) (44)
Peripheral donor leukocytes prolong survival of rat renal allografts. (1999) (44)
Screening for chronic kidney disease in emerging countries: feasibility and hurdles. (2009) (44)
Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease (2014) (43)
Protecting single-kidney allografts from long-term functional deterioration. (1998) (42)
Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. (1992) (42)
Cyclosporine induces glomerulosclerosis: three-dimensional definition of the lesions in a rat model of renal transplant. (1996) (42)
Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. (2013) (41)
Edema of the nephrotic syndrome: the role of the atrial peptide system. (1993) (40)
Mesenchymal stromal cells for tolerance induction in organ transplantation. (2017) (39)
Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides (1994) (39)
Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA (2012) (39)
Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. (2004) (39)
Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. (1992) (38)
ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. (2003) (38)
A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study (2021) (37)
Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. (1995) (37)
Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. (2012) (36)
Ways to Boost Kidney Transplant Viability: A Real Need for the Best Use of Older Donors (2006) (36)
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. (2011) (36)
Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. (1992) (36)
Ticlopidine prevents renal disease progression in rats with reduced renal mass. (1990) (36)
Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. (2001) (36)
L-arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. (1991) (35)
Role of endothelin in glomerular injury. (1993) (35)
Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney. (1988) (35)
The thymic way to transplantation tolerance. (1995) (35)
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. (2016) (34)
Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. (2006) (34)
Maternal and environmental risk factors for neonatal AKI and its long-term consequences (2018) (34)
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. (2003) (33)
Pathophysiology of disease progression in proteinuric nephropathies. (2005) (33)
Endothelin and eicosanoid synthesis in cultured mesangial cells. (1990) (33)
High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. (2005) (33)
Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials. (1989) (32)
Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine. (1994) (32)
Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. (1990) (32)
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial (2019) (32)
Xenotransplantation: problems and prospects. (1997) (31)
Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. (1990) (30)
Mapping disparities in education across low- and middle-income countries (2019) (30)
Prevention programs for chronic kidney disease in low-income countries (2016) (30)
Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy (1992) (30)
Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation. (1990) (30)
In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. (2004) (30)
Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. (1994) (29)
Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note. (1998) (29)
Mesenchymal stromal cells to promote kidney transplantation tolerance (2014) (29)
Endothelin antagonists and renal protection. (2000) (29)
Early and late scanning electron microscopy findings in diabetic kidney disease (2018) (29)
Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? (2005) (29)
Hyperuricemia in kidney transplantation. (2005) (29)
Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression (2001) (28)
Aging and the kidney (2011) (28)
Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. (1999) (28)
Generic cyclosporine formulations: more open questions than answers (2005) (28)
Erratum: Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (The Lancet (2016) 388(10053) (1775–1812)(S0140673616314702)(10.1016/S0140-6736(16)31470-2)) (2017) (27)
CO‐PARTICIPATION OF THROMBOXANE A2 AND LEUKOTRIENE C4 AND D4 IN MEDIATING CYCLOSPORINE‐INDUCED ACUTE RENAL FAILURE (1991) (27)
Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. (2002) (27)
Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. (2001) (26)
Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. (1996) (26)
Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. (2003) (26)
Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study (2017) (25)
Cyclooxygenase products and atrial natriuretic peptide modulate renal response to endothelin. (1990) (25)
A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. (1996) (24)
Glomerular filtration rate gfr extracellular fluid volume ecv and atrial natriuretic factor anf in insulin dependent diabetics (1988) (24)
The future of renoprotection. (2005) (23)
Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection. (2008) (23)
Routine renin-angiotensin system blockade in renal transplantation? (2002) (23)
ACE and SGLT2 inhibitors: the future for non‐diabetic and diabetic proteinuric renal disease (2017) (23)
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. (2009) (23)
Failure to predict cyclosporine area under the curve using a limited sampling strategy. (1993) (23)
Glomerular hyperfiltration (2022) (23)
Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 (2022) (23)
Acute kidney injury: more awareness needed, globally (2015) (22)
Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in rats. (1991) (22)
Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II (2015) (22)
Renal response to atrial peptides is reduced in experimental nephrosis. (1987) (22)
Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago? (2005) (22)
Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019 (2022) (21)
Aldosterone and progression of kidney disease (2009) (21)
Eliminating Treatable Deaths Due to Acute Kidney Injury in Resource‐Poor Settings (2015) (21)
Thymus-mediated immune tolerance to renal allograft is donor but not tissue specific. (1991) (21)
Platelet-activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney. (1997) (21)
Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience (2018) (20)
Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019 (2021) (20)
Non-immune interventions to protect kidney allografts in the long term. (2010) (20)
Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17 (2020) (20)
Assessing Renal Function by GFR Prediction Equations in Kidney Transplantation (2005) (20)
Mortality landscape in the global burden of diseases, injuries and risk factors study. (2014) (20)
Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation (2015) (20)
Losartan in diabetic nephropathy (2004) (19)
Angiotensin II receptor antagonists and treatment of hypertension and renal disease (1998) (19)
A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2) (2021) (19)
Role of platelet-activating factor in renal immune injury and proteinuria. (1990) (18)
Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes. (1990) (18)
Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. (2003) (18)
Renal handling of sodium in the nephrotic syndrome. (1993) (17)
Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: not simply overestimation. (2005) (17)
Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients. (2011) (17)
Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens. (1995) (17)
Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. (2006) (17)
Acute kidney injury in low-income and middle-income countries: no longer a death sentence. (2016) (17)
TRANSPLANTS (1968) (17)
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990-2017. (2020) (16)
Pharmacological and clinical profile of valsartan. (1998) (16)
Management of chronic kidney disease and its risk factors in eastern Nepal. (2014) (16)
Blocking cell microtubule assembly inhibits the alloimmune response in vitro and prolongs renal allograft survival by inhibition of Th1 and sparing of Th2 cell function in vivo. (1995) (16)
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents (2022) (16)
The potential of endothelin antagonism as a therapeutic approach (2004) (15)
Evidence of the central role of the thymus in the induction of donor-specific unresponsiveness to a renal allograft. (1992) (15)
Acquired transplant tolerance (1997) (15)
Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation. (1995) (15)
Colchicine allows prolonged survival of highly reactive renal allograft in the rat. (1993) (15)
Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? (2001) (15)
Prevalence of Hypertension and Diabetes and Coexistence of Chronic Kidney Disease and Cardiovascular Risk in the Population of the Republic of Moldova (2012) (15)
Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration (2019) (14)
Cyclosporine Formulation and Kaposi’s Sarcoma after Renal Transplantation (2005) (14)
Prevention and Transplantation in Chronic Kidney Disease: What Is Achievable in Emerging Countries? (2010) (14)
Efficacy and Tolerability of Valsartan Compared with Lisinopril in Patients with Hypertension and Renal Insufficiency (1997) (14)
Calcitonin gene-related peptide reduces renal vascular resistance and modulates ET-1-induced vasoconstriction. (1994) (13)
CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat. (1996) (13)
Third‐party bone marrow–derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial (2020) (13)
Polycystic kidney disease: Do mTOR inhibitors still have a future in ADPKD? (2010) (13)
Renal metabolism and urinary excretion of platelet-activating factor in the rat. (1990) (13)
Chronic kidney disease in sub-Saharan Africa: a public health priority. (2014) (12)
Hypertension and kidney function in an adult population of West Bengal, India: Role of body weight, waist circumference, proteinuria and rural area living (2013) (12)
Renal handling of aspirin in the rat. (1989) (12)
Limited Sampling Strategies for the Estimation of Sirolimus Daily Exposure in Kidney Transplant Recipients on a Calcineurin Inhibitor—Free Regimen (2009) (12)
Renal metabolism and urinary excretion of thromboxane B2 in the rat. (1989) (12)
Morphometrical analysis of glomerular changes induced by cyclosporine in the rat. (1991) (12)
Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Pro-Tolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. (2019) (12)
Heparin for Hemodialysis: Practical Guidelines for Administration and Monitoring (1984) (12)
Epidemiology of End-Stage Renal Failure: The Burden of Kidney Diseases to Global Health (2017) (12)
Prevention of Transplant Rejection (1997) (11)
Posttransplant immunosuppression in highly sensitized patients. (2009) (11)
Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. (2007) (11)
Emerging drugs for diabetic nephropathy (2005) (11)
Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation (2007) (11)
Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report. (2008) (11)
FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. (1991) (11)
Acute Kidney Injury in Poor Countries Should No Longer Be a Death Sentence: The ISN ‘0 by 25' Project (2015) (11)
Bergamo and Covid-19: How the Dark Can Turn to Light (2020) (11)
Need for chronic kidney disease prevention programs in disadvantaged populations. (2015) (10)
How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? (1998) (10)
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990-2017. (2021) (10)
One or two marginal organs for kidney transplantation? (2002) (10)
International Society of Nephrology's perspective on the emergence of chronic kidney diseases of unknown/undetermined etiology. (2014) (10)
The Lupus Anticoagulant (1984) (10)
Immunomodulation by intrathymic injection of donor leukocytes in rhesus monkeys. (2001) (10)
Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. (2001) (10)
Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries (2017) (9)
Xenotransplantation in the 21st Century (2002) (9)
A RECURRENT QUESTION FROM A PRIMARY CARE PHYSICIAN: HOW SHOULD I TREAT MY COVID-19 PATIENTS AT HOME? (2020) (9)
The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting (2020) (9)
Transplantation tolerance. A complex scenario awaiting clinical applicability. (2005) (8)
Investigational drugs for diabetic nephropathy. (2008) (7)
Calcineurin inhibitors and sirolimus (2003) (7)
Renal Graft Function and Low-Dose Cyclosporine Affect Mycophenolic Acid Pharmacokinetics in Kidney Transplantation (2011) (7)
Proinflammatory mediators of glomerular injury and mechanisms of activation of autoreactive T cells. (1994) (7)
Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial. (2005) (7)
Investigational drugs for diabetic nephropathy (2008) (7)
Studies of privileged sites and organ transplantation. (1993) (7)
Cyclosporine/tacrolimus (FK-506) (1998) (7)
Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells (1992) (7)
Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. (1989) (7)
Renin-angiotensin system and glomerular prostaglandins in early nephrotoxicity of ciclosporin. (1986) (7)
Mesenchymal Stromal Cells for AKI after Cardiac Surgery. (2017) (7)
Tacrolimus and ciclosporin microemulsion in renal transplantation (2002) (7)
Prostacyclin and renal diseases. (1982) (7)
Metabolism of thromboxane B2 in the isolated perfused rat kidney: mass spectrometric identification of urinary products. (1989) (6)
Should We Still Believe in Randomized Controlled Trials in Nephrology? (2016) (6)
Conflict of interest as seen from a researcher’s perspective (2002) (6)
The scientific care for prevention: an overview. (2005) (6)
Kidney prevention recipes for your office practice. (2005) (6)
The possible role of endothelin in the process of progressive renal deterioration in experimental and human glomerulopathies. (1993) (6)
Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives (2004) (6)
The Emergence of Regenerative Medicine in Organ Transplantation: 1st ECTORS meeting. (2020) (6)
The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 (2022) (6)
Antiplatelet agents: effects on the progressive renal disease. (1991) (5)
Intrathymic transplantation of donor cells allows a stabilized, incompatible renal transplant to survive indefinitely after cyclosporine withdrawal. (1993) (5)
Abnormalities of arachidonate metabolism in experimental ciclosporin nephrotoxicity. (1989) (5)
Atrial natriuretic factor in hypertensive and normotensive insulin-dependent diabetics. (1989) (5)
Recent advances in immunosuppression and acquired immune tolerance in renal transplants. (2016) (5)
Effect of fluid shear stress on tubular kidney epithelial cell structure (2009) (5)
Drug development: how academia, industry and authorities interact (2014) (5)
Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients (2006) (5)
Pharmacological Induction of Kidney Regeneration (2017) (5)
Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen. (2010) (4)
Renal cyclophilin-like protein gene expression parallels changes in sodium excretion in experimental nephrosis and is positively modulated by atrial natriuretic peptide. (1993) (4)
The incessant search for renal biomarkers: is it really justified? (2019) (4)
Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence? (2021) (4)
Pathogenesis of Preeclampsia (1986) (4)
Immunotolerance: from new knowledge of mechanisms of self-tolerance to future perspectives for induction of renal transplant tolerance. (1995) (4)
Two-hour post dose cyclosporine monitoring does not fit all in kidney transplantation (2005) (4)
The Glomerulus: Mechanisms and Patterns of Injury (2014) (4)
Tertatolol ameliorates renal function in rats with chronic renal failure. (1988) (3)
ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. (1999) (3)
Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: are there practical implications? (2006) (3)
Proteinuria and Tubulotoxicity (2018) (3)
Epidemiology and outcome - 2 (2009) (3)
The kidney triggers graft-versus-host disease in experimental combined transplantation of kidney and stem cell-enriched peripheral leukocytes. (1996) (3)
High serum cholesterol: a missed risk factor for chronic kidney disease mortality. (2014) (3)
More on renal disease progression: is interstitial inflammation truly protective? (2007) (3)
A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies. (2022) (3)
Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. (2007) (3)
Humoral immunity in kidney transplantation: what clinicians need to know. Preface. (2008) (3)
[Functional loss of the transplanted kidney: immunological and non-immunological factors]. (2004) (2)
Optimization of cyclosporine therapy in kidney transplantation. (1998) (2)
Vascular endothelin and renal disease progression. (1992) (2)
Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugs (1996) (2)
Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients (2016) (2)
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting (2013) (2)
[Strategies for a greater supply of organs for transplantation]. (2001) (2)
The Bergamo Kidney Transplant Program. (2005) (2)
In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine (2021) (2)
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial (2023) (2)
COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients? (2021) (2)
Nitric oxide and renal perfusion in humans. (2002) (2)
Humoral Immunity in Kidney Trasplantation: What Clinicians Need to Know (2008) (2)
A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases (2018) (1)
Mechanisms and Consequences of Proteinuria (2011) (1)
Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort Study (2021) (1)
Effects of tertatolol on renal function in the isolated perfused rat kidney. (1989) (1)
Induction of unresponsiveness via intrathymic inoculation (1991) (1)
The role of mTOR inhibition in the control of autosomal dominant polycystic kidney disease (2010) (1)
The kidney transplant program at the Bergamo Center. (2000) (1)
Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. (1998) (1)
[Renal transplantation in Autosomal Dominant Polycystic Kidney Disease (ADPKD)]. (2016) (1)
Generation of Regulatory T Cells Semiallogeneic Heart Transplant through the Cells Prolongs the Survival of a Pretransplant Infusion of Mesenchymal Stem (2008) (1)
[Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors]. (2016) (1)
Role of endothelin (ET) in the progression of renal disease (1990) (1)
Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial (2023) (1)
Clinical Kidney Xenotransplantation: Major Progress but More Work Needs to Be Done (2022) (1)
Department of Error (2017) (1)
MO023FLANK PAIN HAS A MAJOR NEGATIVE IMPACT ON HEALTH-RELATED QUALITY OF LIFE IN ADPKD: THE CYSTIC I STUDY (2021) (1)
Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study (2022) (1)
Octreotide Lar in Patients with Autosomal Dominant Polycystic Kidney Disease: From Bench to A Novel Perspective of Therapy (2022) (1)
Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. (2004) (1)
Prevention of Chronic Renal Diseases in the Elderly (2008) (1)
Corrigendum to “Let’s assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?” [J Hepatol 44 (2006) 837–838] (2006) (0)
The need for a multi-disciplinary reflection about frailty and cognitive impairment in chronic kidney disease (2022) (0)
Epidemiology and CKD - 3 (2009) (0)
MYCOPHENOLIC ACID FORMULATIONS AFFECT CYCLOSPORINE PHARMACOKINETICS IN STABLE KIDNEY TRANSPLANT RECIPIENTS. (2006) (0)
Full-dose NSAIDs at the first sign of respiratory infection? – Authors’ reply (2022) (0)
Dexamethasone prevents platelet-activating factor induced proteinuria in isolated perfused rat kidney (1995) (0)
Renal prostaglandins and hyperfiltration. (1987) (0)
Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. (1992) (0)
Systemic and Renal Response of GAL-KO Pigs To Human Angiotensin II.: Abstract# D2856 (2014) (0)
Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis (2022) (0)
Low birth weight, nephron number and chronic kidney disease (2022) (0)
Present and future of CONNECT: a new and compelling project of modern medicine (2021) (0)
Consultants for the American Journal of Nephrology 2007 (2007) (0)
Altered Renovascular Endothelial Functions During Nephrotoxicity (1991) (0)
Acute Renal Failure in Kidney Transplant Recipients (2019) (0)
Early and late scanning electron microscopy findings in diabetic kidney disease (2018) (0)
Propionyl-L-carnitine prevents renal ischemia/reperfusion injury in a rat model of syngeneic kidney transplantation (2000) (0)
Absolute differences between measured and estimated GFR values vs baseline measured GFR. (2012) (0)
Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies (2012) (0)
Salty tea intake and hypertension in Mongolia (2009) (0)
Contents Vol. 136, 2017 (2017) (0)
Lab methods, progression & risk factors for CKD - 2 (2009) (0)
Models of human renal disease (1990) (0)
The Glomerulus: Mechanisms of Injury (2010) (0)
Effect of ticlopidine on the evolution of renal disease in rats with reduced renal mass. (1990) (0)
to reduced GFR (2017) (0)
Tacrolimus and ciclosporin microemulsion in renal transplantation. Author's reply (2002) (0)
Immune Modulatory Cell Therapy in Kidney Transplantation: Hints of a Durable Mechanism of Action (2023) (0)
Increased urinary excretion of thromboxane B 2 and 2 , 3-dinor-TxB 2 in cyclosporin A nephrotoxicity (2010) (0)
MDR1 POLYMORPHISMS INFLUENCES DAILY CYCLOSPORINE EXPOSURE IN STABLE KIDNEY TRANSPLANT RECIPIENTS. (2006) (0)
LIMITED SAMPLING STRATEGIES FOR THE ESTIMATION OF SIROLIMUS EXPOSURE IN KIDNEY TRANSPLANT RECIPIENTS. (2006) (0)
RoleofEndothelium-derived Nitric OxideintheBleeding TendencyofUremia (1990) (0)
Mineral and bone disease - CKD 1-5 (2012) (0)
Epidemiology and CKD - 2 (2009) (0)
Epidemiology and CKD - 2 (2009) (0)
Diffusion magnetic resonance imaging for kidney cyst volume quantification and non-cystic tissue characterisation in ADPKD. (2023) (0)
Molecular Medicine in Organ Transplantation: How and When? (2001) (0)
Worldwide cardiovascular and ESRD outcomes attributable to reduced GFR Running Title: Reduced GFR-attributed health loss (2018) (0)
Semi-Automated Quantification of Cyst Volume from T2-Weighted MR Images in ADPKD (2008) (0)
Coichicine Interferes with L-Selectin and Leukocyte Function-Associated Antigen-i Expression on Human I Lymphocytes a nd Inhibits I Cell (1996) (0)
An Artificial Intelligence Algorithm for ADPKD: Are We Close to Successful Clinical Implementation? (2023) (0)
Pre-clinical studies on end-organ protective effects from AT1-receptor blockade. (2000) (0)
Addressing acute kidney injury in critically ill newborn babies. (2017) (0)
Structure and Function in ADPKD: Correlation Between GFR and Relative Volume of Hypo-Enhanced Paranchyma from Contrast-Enhanced CT Imaging (2008) (0)
Erratum: Correction to Lancet HIV ((2016) 3 (e361–87)(S235230181630087X)(10.1016/S2352-3018(16)30087-X) (2016) (0)
A Logistic-Regression Model Provides Novel Guidelines to Maximize the Anti-Acute Rejection Properties of Cyclosporine with a Minimum of Toxicity1 (2005) (0)
Contents Vol. 27, 2007 (2007) (0)
Links Between Bolivia, Moldova, and Italy for Prevention of Chronic Nephropathies (2005) (0)
Maintenance Immunosuppression in Kidney Transplantation (2017) (0)
SAT-148 Determinants of outcomes in pediatric chronic kidney disease [CKD] in a low resource setting (2020) (0)
Vasoactive and Inflammatory Substances (2004) (0)
Immunomodulation by intrathymic donor leukocytes in rhesus monkeys (1997) (0)
Development Donor-Specific Anti-HLA Antibody Associates with a High Incidence of De Novo Depletion and Regeneration , Which Anti-Thymocyte Globulin Induces B Cell but Not Basiliximab / Low-Dose Rabbit In Kidney Transplant Patients , Alemtuzumab (2013) (0)
Epidemiology and CKD - 1 (2009) (0)
Pharmacologic Monitoring of Immunosuppressive Drugs (2001) (0)
Monkeypox in pregnancy: update on (2022) (0)
Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017 (2020) (0)
Decreased Nephron Number within Physiologic Ranges Increases Susceptibility to Chronic Renal Diseases Later in Life (2020) (0)
Pharmacokinetic study of the new cyclosporine-a formulation (neoral™) in adult ALLO-BMT recipients (2000) (0)
Links Between Bolivia, Moldova and Italy for Prevention of Chronic Nephropathies (2005) (0)
The lupus anticoagulant (41879) (1984) (0)
Mechanisms and Mediators of Cyclosporine-Induced Renal Vascular Changes (1991) (0)
Donor hematopoietic cells: central versus peripheral tolerance (2004) (0)
Renal transplantation - basic research (2009) (0)
Editorial: Insights in renal pharmacology: 2021 (2022) (0)
Subject Index Vol. 27, 2007 (2007) (0)
Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation (2016) (0)
Subject Index Vol. 162, 2009 (2009) (0)

This paper list is powered by the following services:

Norberto Perico's Academic­Influence.com Rankings

Why Is Norberto Perico Influential?

Norberto Perico's Published Works

Published Works

Norberto Perico's AcademicInfluence.com Rankings